8-K: Predictive Oncology Reports Q1 2024 Results, Highlights AI and Biologics Progress

Predictive Oncology announced its first quarter 2024 financial results, reporting a net loss of $4.2 million on revenue of $0.4 million, while also highlighting advancements in AI-driven drug discovery and biologics capabilities.

Summary

• Predictive Oncology reported a net loss of approximately $4.2 million for the first quarter of 2024, with total revenue of approximately $0.4 million.
• The company's cash balance decreased from $8.7 million at the end of 2023 to $5.2 million by the end of the first quarter of 2024.
• Stockholders' equity also decreased from $8.3 million to $4.1 million over the same period.
• The net loss per share was $(1.04) for Q1 2024, compared to $(0.86) for Q1 2023.
• Revenue increased to $419,646 in Q1 2024 from $239,895 in Q1 2023, primarily from the Eagan operating segment.
• Gross profit margin improved to 55% in Q1 2024 from 50% in Q1 2023, due to a change in sales mix.
• Operating expenses increased to $4.5 million in Q1 2024 from $3.6 million in Q1 2023, driven by higher general and administrative, operations, and sales and marketing expenses.
• Net cash used in operating activities was $3.4 million in both Q1 2024 and Q1 2023.

Sentiment

Score: 4

Explanation: The document presents mixed results with increased revenue and gross profit margin, but also a significant net loss and decrease in cash and equity. The positive collaborations and AI advancements are promising, but the financial situation is concerning.

Positives

• Revenue increased to $419,646 in Q1 2024, compared to $239,895 in Q1 2023.
• Gross profit margin improved to 55% in Q1 2024 from 50% in Q1 2023.
• The company has made progress in its collaborations with Fujifilm and FluGen.
• The company's AI models have shown potential as decision support tools in clinical practice.
• The company is in late-stage discussions on a number of engagements.

Negatives

• The company reported a net loss of $4.2 million for the first quarter of 2024.
• The company's cash balance decreased to $5.2 million by the end of Q1 2024.
• Stockholders' equity decreased to $4.1 million by the end of Q1 2024.
• The net loss per share was $(1.04) for Q1 2024, compared to $(0.86) for Q1 2023.
• Operating expenses increased to $4.5 million in Q1 2024 from $3.6 million in Q1 2023.

Risks

• The company's future performance may materially differ from forward-looking statements due to risks related to collaboration arrangements, commercialization activities, and product sales levels.
• The company is subject to risks related to the success of its collaboration arrangements.
• The company is subject to risks related to commercialization activities and product sales levels by its collaboration partners.

Future Outlook

The company anticipates accelerating contracting momentum throughout 2024 and is in late-stage discussions on a number of engagements across both of its businesses. They also see an opportunity to identify novel biomarkers which may allow them, or a licensing partner, to develop new cancer therapies.

Management Comments

• Our first quarter 2024 and subsequent results reflect the breadth and versatility of our technology, from the development of AI-driven machine learning models that can accelerate and de-risk early drug discovery, to our suite of biologics formulations and manufacturing capabilities that support leading biopharmaceutical drug developers and improve their chances of clinical success, said Raymond F. Vennare, Chief Executive Officer and Chairman of Predictive Oncology.
• Our recent announcements of projects with Fujifilm and FluGen, in particular, suggest that demand for our biologics solutions is strong while we continue to advance discussions with UPMC Magee-Womens Hospital and others on next steps following recent successful PEDAL engagements.
• Since we implemented our new strategic vision for the company at the beginning of 2023, we have continued to refine our business development efforts, and we are making steady progress conveying to current and prospective partners the unique blend of assets and capabilities that we possess.
• I look forward to accelerating contracting momentum as we progress through 2024, concluded Mr. Vennare.

Industry Context

This announcement highlights Predictive Oncology's focus on leveraging AI and machine learning in drug discovery, a growing trend in the pharmaceutical industry. The collaborations with Fujifilm and FluGen demonstrate the company's ability to partner with established players in the biopharmaceutical space. The presentation at ASCO also positions the company as a thought leader in the application of AI to cancer research.

Comparison to Industry Standards

• Predictive Oncology's Q1 2024 revenue of $0.4 million is relatively low compared to established pharmaceutical companies, but is typical for a company in the early stages of commercializing its technology.
• The net loss of $4.2 million is also typical for a company investing heavily in research and development.
• The company's gross profit margin of 55% is competitive with other companies in the biotechnology sector.
• The collaborations with Fujifilm and FluGen are positive indicators of the company's potential to generate future revenue.
• The acceptance of the abstract at ASCO is a significant achievement and demonstrates the company's scientific credibility.

Stakeholder Impact

• Shareholders will be concerned about the increased net loss and decreased cash balance.
• Employees may be impacted by the company's financial performance.
• Customers may benefit from the company's advancements in AI and biologics.
• Suppliers may be impacted by the company's financial performance.
• Creditors may be concerned about the company's financial performance.

Next Steps

• The company will continue to advance discussions with UPMC Magee-Womens Hospital and others on next steps following recent successful PEDAL engagements.
• The company will continue to refine its business development efforts.
• The company will accelerate contracting momentum as it progresses through 2024.

Key Dates

Keywords

Predictive Oncology, AI, Machine Learning, Drug Discovery, Biologics, Oncology, Flu Vaccine, Endotoxin Testing, ASCO, Financial Results